Skip to main content
main-content

Diabetes

Latest articles

25-03-2019 | Diabetes | News | Article

Real-world data highlight closed-loop frustrations for youth users

System problems and irritations lead to nearly two in five children abandoning use of closed-loop insulin delivery in a real-world setting, researchers have reported.

25-03-2019 | Diabetes | News | Article

Problem of hypoglycemia unawareness highlighted in older people with type 1 diabetes

Baseline data from the WISDM trial show that older adults with type 1 diabetes who have impaired awareness of hypoglycemia symptoms can spend over half an hour per day with extremely low blood glucose levels.

22-03-2019 | Cardiovascular | News | Article

HIIT plus resistance training may have cardiovascular benefits in type 2 diabetes

A 1-year exercise intervention combining high-intensity interval training with resistance training may improve measures of cardiovascular risk among people with type 2 diabetes, suggests a secondary analysis of the D2FIT trial.

21-03-2019 | Diabetes | News | Article

Microvascular disease a marker of heart failure risk in type 2 diabetes

The presence of microvascular disease in people with type 2 diabetes signals a high risk for heart failure, report the EMPA-REG OUTCOME investigators.

20-03-2019 | Diabetes | News | Article

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.

19-03-2019 | Diabetes | News | Article

Benefits of full target monitoring shown in type 2 diabetes

Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.

18-03-2019 | Diabetes | News | Article

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

17-03-2019 | Diabetes | News | Article

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

15-03-2019 | Diabetes | News | Article

Targeted insulin-adherence intervention may improve glycemic control

Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.

14-03-2019 | Diabetes | News | Article

Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes

Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.

13-03-2019 | Diabetes | News | Article

ABCD audit data reveal improved glycemic control with use of FreeStyle Libre, canagliflozin

Analyses of real-world audit data show positive initial results for the flash glucose monitoring system FreeStyle Libre and the sodium-glucose cotransporter 2 inhibitor canagliflozin.

13-03-2019 | Diabetes | News | Article

Tailored CBT reduces depression, distress in type 2 diabetes

A patient-specific cognitive behavioral therapy and lifestyle counseling intervention can significantly improve psychological outcomes in type 2 diabetes patients with depression and/or regimen-related distress, say researchers.

12-03-2019 | Diabetes | News | Article

Adding second diabetes medication better than switching in face of poor response

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

12-03-2019 | Diabetes | News | Article

Nurse-led intervention can reduce mortality risk after severe hypoglycemia

Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.

11-03-2019 | Diabetes | News | Article

Autoantibodies in pregnancy signal high risk for impending type 1 diabetes

Women with gestational diabetes who also have autoantibodies are highly likely to go on and develop type 1 diabetes, research shows.

11-03-2019 | Diabetes | News | Article

Modifiable cardiometabolic risk factors dominant type 1 diabetes mortality risk

The strongest predictors for mortality and cardiovascular disease disease in patients with type 1 diabetes are generally modifiable cardiometabolic risk factors, researchers report.

08-03-2019 | Diabetes | News | Article

CONCEPTT data show substantial cost savings with CGM in pregnancy

Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.

08-03-2019 | Diabetes | News | Article

Similar weight-loss outcomes with one anastomosis, Roux-en-Y gastric bypass procedures

Findings from the YOMEGA trial indicate that the one anastomosis gastric bypass procedure is noninferior to standard Roux-en-Y gastric bypass in terms of weight loss and metabolic outcomes.

08-03-2019 | Diabetes | News | Article

TrialNet monitoring study shows risk-reducing effect of type 1 diabetes screening

Data from the TrialNet Pathway to Prevention study shows that monitoring high-risk relatives of people with type 1 diabetes markedly reduces the risk for those who develop the condition presenting with diabetic ketoacidosis.

08-03-2019 | Diabetes | News | Article

The DiRECT trial in practice

Following the positive 2-year results of DiRECT, this symposium shared the first-hand experiences of a dietician, a general practitioner, and a person with diabetes who participated in the DiRECT study.